Literature DB >> 23279339

Transthyretin-related familial amyloidotic polyneuropathy: description of a cohort of patients with Leu64 mutation and late onset.

Massimo Russo1, Anna Mazzeo, Claudia Stancanelli, Rita Di Leo, Luca Gentile, Gianluca Di Bella, Fabio Minutoli, Sergio Baldari, Giuseppe Vita.   

Abstract

Transthyretin-related familial amyloidotic polyneuropathy (TTR-FAP) usually presents itself as a progressive sensorimotor polyneuropathy with severe autonomic dysfunction and cardiomyopathy. Eighteen patients carrying the Leu64 mutation underwent a series of regular follow-ups, including: neurological examination, electroneurography, electromyography, electrocardiography and echocardiography, blood analysis, a questionnaire on autonomic symptoms, cardiovascular autonomic tests and a 99mTc-DPD examination study. A late onset of a slowly progressive disease which reached its terminal stage after about 10  years was observed. The onset was mainly a length-dependent sensory neuropathy, although a focal onset with carpal tunnel syndrome was detected in three patients. At the onset of the disease, autonomic dysfunction was present in a small number of patients, but, within a few years, this had manifested in all members of the sample group. The only extra-neurological manifestations were cardiac related. It is reasonable to consider Southern Italy as an endemic focus of TTR-FAP. An underestimation of disease prevalence could be caused by a late onset of FAP, which can manifest in patients up to their late 70s. Follow-up of asymptomatic individuals may permit the early detection of symptoms and signs, allowing a detailed record of the natural history of the disease from the beginning and facilitating prompt treatment.
© 2012 Peripheral Nerve Society.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23279339     DOI: 10.1111/j.1529-8027.2012.00436.x

Source DB:  PubMed          Journal:  J Peripher Nerv Syst        ISSN: 1085-9489            Impact factor:   3.494


  13 in total

1.  Non-coding variants contribute to the clinical heterogeneity of TTR amyloidosis.

Authors:  Andrea Iorio; Antonella De Lillo; Flavio De Angelis; Marco Di Girolamo; Marco Luigetti; Mario Sabatelli; Luca Pradotto; Alessandro Mauro; Anna Mazzeo; Claudia Stancanelli; Federico Perfetto; Sabrina Frusconi; Filomena My; Dario Manfellotto; Maria Fuciarelli; Renato Polimanti
Journal:  Eur J Hum Genet       Date:  2017-06-21       Impact factor: 4.246

Review 2.  Echocardiographic Findings in Cardiac Amyloidosis: Inside Two-Dimensional, Doppler, and Strain Imaging.

Authors:  Dalia Di Nunzio; Antonino Recupero; Cesare de Gregorio; Concetta Zito; Scipione Carerj; Gianluca Di Bella
Journal:  Curr Cardiol Rep       Date:  2019-02-12       Impact factor: 2.931

3.  Patisiran in hATTR Amyloidosis: Six-Month Latency Period before Efficacy.

Authors:  Luca Gentile; Massimo Russo; Marco Luigetti; Giulia Bisogni; Andrea Di Paolantonio; Angela Romano; Valeria Guglielmino; Ilenia Arimatea; Mario Sabatelli; Antonio Toscano; Giuseppe Vita; Anna Mazzeo
Journal:  Brain Sci       Date:  2021-04-19

4.  Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic area.

Authors:  A Cortese; G Vita; M Luigetti; M Russo; G Bisogni; M Sabatelli; F Manganelli; L Santoro; T Cavallaro; G M Fabrizi; A Schenone; M Grandis; C Gemelli; A Mauro; L G Pradotto; L Gentile; C Stancanelli; A Lozza; S Perlini; G Piscosquito; D Calabrese; A Mazzeo; L Obici; D Pareyson
Journal:  J Neurol       Date:  2016-03-16       Impact factor: 4.849

5.  Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis.

Authors:  Giorgio Treglia; Andor W J M Glaudemans; Francesco Bertagna; Bouke P C Hazenberg; Paola A Erba; Raffaele Giubbini; Luca Ceriani; John O Prior; Luca Giovanella; Riemer H J A Slart
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-04-23       Impact factor: 9.236

6.  Baseline Characteristics and Secondary Medication Adherence Patterns Among Patients Receiving Tafamidis Prescriptions: A Retrospective Analysis Using a National Specialty Pharmacy Dispensing Database.

Authors:  Anuja Roy; Andrew Peterson; Nick Marchant; Jose Alvir; Rahul Bhambri; Jason Lynn; Darrin Benjumea; Sapna Prasad; Alex O'Brien; Yong Chen; Jason Kemner; Bhash Parasuraman
Journal:  Patient Prefer Adherence       Date:  2022-04-29       Impact factor: 2.314

7.  Serial scanning with technetium pyrophosphate (99mTc-PYP) in advanced ATTR cardiac amyloidosis.

Authors:  Adam Castaño; Albert DeLuca; Richard Weinberg; Ted Pozniakoff; William S Blaner; Altaf Pirmohamed; Brian Bettencourt; Jared Gollob; Verena Karsten; John A Vest; Codruta Chiuzan; Mathew S Maurer; Sabahat Bokhari
Journal:  J Nucl Cardiol       Date:  2015-10-09       Impact factor: 5.952

8.  Use of Drugs for ATTRv Amyloidosis in the Real World: How Therapy Is Changing Survival in a Non-Endemic Area.

Authors:  Massimo Russo; Luca Gentile; Vincenzo Di Stefano; Gianluca Di Bella; Fabio Minutoli; Antonio Toscano; Filippo Brighina; Giuseppe Vita; Anna Mazzeo
Journal:  Brain Sci       Date:  2021-04-27

9.  Autonomic involvement in subacute and chronic immune-mediated neuropathies.

Authors:  Anna Mazzeo; Claudia Stancanelli; Rita Di Leo; Giuseppe Vita
Journal:  Autoimmune Dis       Date:  2013-06-18

10.  Early Impairment of Right Ventricular Morphology and Function in Transthyretin-Related Cardiac Amyloidosis.

Authors:  Roberto Licordari; Fabio Minutoli; Antonino Recupero; Mariapaola Campisi; Rocco Donato; Anna Mazzeo; Giuseppe Dattilo; Sergio Baldari; Giuseppe Vita; Concetta Zito; Gianluca Di Bella
Journal:  J Cardiovasc Echogr       Date:  2021-05-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.